Guidance
Update information
Minor changes since publication
August 2023: We added links to the MHRA safety advice on DOACs and NICE's technology appraisal guidance on andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697) to the section on anticoagulant reversal in hospital settings.
November 2020: We clarified our advice in recommendation 1.5.23 on crystalloids and tetrastarches for patients with or without active bleeding.
ISBN: 978-1-4731-1680-1